| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176776.8AEP2687511A1 (en) | 2012-07-17 | 2012-07-17 | Pyridinone derivatives as tissue transglutaminase inhibitors |
| US201261741871P | 2012-07-30 | 2012-07-30 | |
| PCT/EP2013/064789WO2014012858A1 (en) | 2012-07-17 | 2013-07-12 | Pyridinone derivatives as tissue transglutaminase inhibitors |
| Publication Number | Publication Date |
|---|---|
| IN2015DN01151Atrue IN2015DN01151A (en) | 2015-06-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1151DEN2015IN2015DN01151A (en) | 2012-07-17 | 2015-02-12 |
| Country | Link |
|---|---|
| US (1) | US9434763B2 (en) |
| EP (2) | EP2687511A1 (en) |
| JP (1) | JP6236445B2 (en) |
| CN (1) | CN104603109B (en) |
| AU (1) | AU2013292149B2 (en) |
| CA (1) | CA2878796C (en) |
| CY (1) | CY1116775T1 (en) |
| DK (1) | DK2797892T3 (en) |
| ES (1) | ES2543956T3 (en) |
| HR (1) | HRP20150829T1 (en) |
| HU (1) | HUE027051T2 (en) |
| IL (1) | IL236707B (en) |
| IN (1) | IN2015DN01151A (en) |
| PL (1) | PL2797892T3 (en) |
| PT (1) | PT2797892E (en) |
| RS (1) | RS54153B1 (en) |
| RU (1) | RU2652987C2 (en) |
| SI (1) | SI2797892T1 (en) |
| SM (1) | SMT201500208B (en) |
| WO (1) | WO2014012858A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3331881B1 (en) | 2015-08-05 | 2019-05-15 | ratiopharm GmbH | New crystalline form and acetic acid adducts of palbociclib |
| WO2019201432A1 (en)* | 2018-04-17 | 2019-10-24 | Zedira Gmbh | Inhibitors of blood coagulation factor xiii |
| TWI825144B (en) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | Transglutaminase 2 (tg2) inhibitors |
| WO2020239103A1 (en)* | 2019-05-31 | 2020-12-03 | 四川海思科制药有限公司 | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
| EP3900707A1 (en)* | 2020-04-24 | 2021-10-27 | Dr. Falk Pharma Gmbh | Systemic formulation of a pyridinone derivate for tg2-related diseases |
| EP3900706A1 (en)* | 2020-04-24 | 2021-10-27 | Dr. Falk Pharma Gmbh | Systemic formulation of a pyridinone derivate for coeliac disease |
| AU2021260856B2 (en)* | 2020-04-24 | 2024-12-12 | Dr. Falk Pharma Gmbh | Systemic formulation of a pyridinone derivate for coeliac disease |
| EP3965742B1 (en)* | 2020-04-24 | 2023-06-14 | Dr. Falk Pharma Gmbh | Systemic formulation of a pyridinone derivate for tg2-related diseases |
| CN117561241A (en)* | 2021-06-30 | 2024-02-13 | 策迪拉有限公司 | transglutaminase inhibitor |
| FI4192814T3 (en) | 2021-06-30 | 2024-10-31 | Zedira Gmbh | TRANSGLUTAMINASE INHIBITORS |
| WO2023275333A1 (en)* | 2021-06-30 | 2023-01-05 | Zedira Gmbh | Inhibitors of transglutaminases |
| US20240376055A1 (en) | 2021-06-30 | 2024-11-14 | Zedira Gmbh | Inhibitors of transglutaminases |
| WO2023110138A1 (en)* | 2021-12-17 | 2023-06-22 | Zedira Gmbh | Inhibitors of transglutaminases |
| WO2023072368A1 (en)* | 2021-10-25 | 2023-05-04 | Dr. Falk Pharma Gmbh | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
| WO2025153465A1 (en) | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021440A (en)* | 1989-07-31 | 1991-06-04 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| AU743735B2 (en)* | 1996-10-11 | 2002-02-07 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
| AR032318A1 (en)* | 2000-04-13 | 2003-11-05 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-5,6; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF NITRICAL SYNTHEASE OXIDE |
| AU2003234597A1 (en)* | 2002-05-14 | 2003-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| US7265093B2 (en)* | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
| PE20050159A1 (en)* | 2003-05-27 | 2005-04-19 | Vertex Pharma | DERIVATIVES OF 3- [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-IL) -ACETILAMINO] -4-OXO-PENTANOICO AS CASPASE INHIBITORS |
| EP1781807B1 (en) | 2004-08-11 | 2008-12-03 | N-Zyme BioTec GmbH | Fluorescence-based kinetic determination of transglutaminase activity |
| DE102006052755A1 (en)* | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | New peptide derivatives and peptidomimetics are transglutaminase inhibitors useful for the treatment or prophylaxis of e.g. celiac disease, fibrosis, thrombosis, neurodegenerative disorders, Huntington's chorea and Parkinson disease |
| JP2013180955A (en)* | 2012-02-29 | 2013-09-12 | Toray Ind Inc | Tissue transglutaminase inhibitor, chalcone derivative, and pharmaceutical application thereof |
| Publication number | Publication date |
|---|---|
| AU2013292149A1 (en) | 2015-02-05 |
| HUE027051T2 (en) | 2016-08-29 |
| DK2797892T3 (en) | 2015-07-20 |
| RU2652987C2 (en) | 2018-05-04 |
| WO2014012858A1 (en) | 2014-01-23 |
| PT2797892E (en) | 2015-09-18 |
| SI2797892T1 (en) | 2015-09-30 |
| PL2797892T3 (en) | 2015-10-30 |
| US9434763B2 (en) | 2016-09-06 |
| ES2543956T3 (en) | 2015-08-26 |
| RS54153B1 (en) | 2015-12-31 |
| CA2878796A1 (en) | 2014-01-23 |
| JP6236445B2 (en) | 2017-11-22 |
| IL236707A0 (en) | 2015-02-26 |
| EP2797892B1 (en) | 2015-05-27 |
| SMT201500208B (en) | 2015-10-30 |
| US20150203535A1 (en) | 2015-07-23 |
| IL236707B (en) | 2018-12-31 |
| JP2015529645A (en) | 2015-10-08 |
| EP2797892A1 (en) | 2014-11-05 |
| HRP20150829T1 (en) | 2015-09-11 |
| CY1116775T1 (en) | 2017-03-15 |
| RU2015104969A (en) | 2016-09-10 |
| CA2878796C (en) | 2018-10-23 |
| EP2687511A1 (en) | 2014-01-22 |
| AU2013292149B2 (en) | 2016-11-24 |
| CN104603109B (en) | 2017-07-28 |
| CN104603109A (en) | 2015-05-06 |
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01151A (en) | ||
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MX2020010535A (en) | Methods of treating cancer. | |
| IN2015DN01156A (en) | ||
| CA2871471C (en) | Dna-pk inhibitors | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| EA024842B9 (en) | Compounds as modulators of pi3k protein kinase | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2014MN02598A (en) | ||
| GEP201706688B (en) | Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer | |
| MX2014005928A (en) | Heterocyclic inhibitors of glutaminase. | |
| IN2014MN00988A (en) | ||
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| IN2015DN01119A (en) | ||
| MX2015007916A (en) | Peri-carbinols. | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| MX348451B (en) | Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists. | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MX2014013758A (en) | Thiazolecarboxamide derivatives for use as nampt inhibitors. | |
| IN2014DN08443A (en) | ||
| IN2014DN03010A (en) | ||
| MX348841B (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. |